Skip to content
N1 Life
All Insights

Research & Industry

Ruxolitinib Cream Advances in Hidradenitis Suppurativa

Ruxolitinib cream is being studied in hidradenitis suppurativa, where lesion location and daily use shape topical development.

  • hidradenitis suppurativa
  • topical treatment
  • clinical development

A condition that changes daily life

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that can cause painful, recurring nodules and abscesses, often in areas such as the armpits and groin. Friction, pain and drainage can affect movement, clothing and everyday routines. Treatment choices need to reflect both disease severity and the realities of the affected sites. [1]

One medicine being investigated for mild-to-moderate HS is ruxolitinib cream. Already used for other skin conditions in some markets, the topical JAK1/2 inhibitor is now the subject of two phase 3 HS studies. [2, 3]

What a topical study measured

A randomized, double-blind phase 2 trial enrolled 69 adults with Hurley stage I or II HS, three to ten abscesses or inflammatory nodules, and no draining tunnels. Participants applied 1.5% ruxolitinib cream or vehicle twice daily. [2]

At week 16, the model-estimated mean reduction in abscess and inflammatory nodule count was 3.61 with ruxolitinib and 2.42 with vehicle. The trial provides a defined clinical signal for a particular patient group and lesion profile. [2]

In 2026, joint guidelines from the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation made a conditional recommendation for topical ruxolitinib alongside other treatment recommendations. Incyte’s third-quarter update said the two phase 3 trials, TRuE-HS1 and TRuE-HS2, were ongoing, with topline results expected in the fourth quarter of 2026. A guideline recommendation and an approved indication are separate decisions. [1, 3]

Designing for affected skin and daily use

HS lesions can occur where skin folds and rubs against clothing. For a topical product, the ease of applying a formulation to tender areas and the demands of repeated use deserve attention alongside clinical response. Measures such as lesion counts can be complemented by pain and everyday function to show how treatment fits a patient’s life.

For development teams, this creates a concrete role for formulation research: understand the drug’s distribution and local exposure, develop a suitable dosage form, and connect those measurements with the outcomes studied in patients. The ongoing trials will add evidence for where this particular cream may fit.

Sources

  1. Naik HB, et al. Joint AAD–Hidradenitis Suppurativa Foundation guidelines. Journal of the American Academy of Dermatology. 2026.
  2. Porter ML, et al. Ruxolitinib cream in mild-to-moderate hidradenitis suppurativa: a phase 2 study. Journal of the American Academy of Dermatology.
  3. Incyte. Third-quarter 2026 financial and corporate update.
  4. N1 Life. 芦可替尼瞄准化脓性汗腺炎的巨大市场. WeChat, November 5, 2026.